Harmony Biosciences stock (US41319J1088): Q1 2026 earnings miss and modest price move on Nasdaq

Harmony Biosciences shares on the Nasdaq in the United States have been trading in the mid-30 USD range in recent sessions, following the company’s Q1 2026 earnings release on 05/07/2026 that showed an EPS of USD 0.55 versus a consensus forecast of USD 0.76, keeping attention on how the US biopharmaceutical group manages growth and profitability in its core sleep disorder portfolio, according to MarketBeat as of 05/30/2026.MarketBeat as of 05/30/2026

The stock last closed at USD 31.61 on Nasdaq on 05/29/2026, posting a marginal move of 0.06 percent on the day, which signals a relatively calm reaction in the United States market as investors digest the earnings miss but also look at the broader trajectory of revenue from narcolepsy treatment Wakix and potential pipeline contributions, according to MarketBeat as of 05/29/2026.MarketBeat as of 05/29/2026

The stock traded at 31.61 USD on 05/29/2026 on Nasdaq, according to MarketBeat as of 05/29/2026.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

Harmony Biosciences: core business model

Harmony Biosciences focuses on developing and commercializing therapies for rare neurological and sleep-wake disorders, with revenue currently anchored by Wakix prescriptions for narcolepsy patients in the United States.

What banks and research houses say about Harmony Biosciences

According to MarketBeat as of 05/30/2026, Harmony Biosciences is covered by a range of US and international research houses, and the consensus view compiled by the platform points to an overall positive stance on the stock with an average 12-month price target above the latest Nasdaq trading level, reflecting expectations of continued revenue expansion from Wakix and potential upside from lifecycle management and new indications.MarketBeat as of 05/30/2026

While individual analyst reports from major US banks are proprietary, the aggregated data underline that a number of US-based brokers continue to model double-digit percentage revenue growth for Harmony Biosciences in 2026, building on the Q1 2026 revenue figure cited by several outlets of around USD 215 million and assuming steady demand in the United States narcolepsy market alongside limited near-term generic risk.Insider Monkey as of 05/20/2026

Conclusion

Harmony Biosciences’ Q1 2026 results, with EPS coming in at USD 0.55 against a consensus of USD 0.76, have so far translated into only modest share price fluctuations on Nasdaq, suggesting that United States investors are balancing the earnings shortfall against the company’s still-growing narcolepsy franchise and broader pipeline prospects.

The analyst consensus data compiled by MarketBeat as of late May 2026 indicate that research houses continue to model revenue expansion and see room for upside relative to the latest market price, but the Q1 earnings miss highlights execution and cost-control questions that the market will monitor closely ahead of the next quarterly release.

For now, Harmony Biosciences remains a United States-based specialty biopharmaceutical play closely tied to Wakix performance, and the stock’s medium-term path on Nasdaq will likely depend on how management converts its rare-disease focus and pipeline into sustained top-line and earnings growth.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.